Staging ::: VER CORREOS
España
Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
230 / 17.039
#1834

Re: Farmas USA

Top 25
Solrac

Información detallada sobre las ponencias a presentar por EXCEL en el ASCO.

Jorge, I am loving your opinion in advance ;)
----------------------------------------------------------------------------

Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting
-- Oral Presentations for Medullary Thyroid Cancer, Castration-Resistant Prostate Cancer, Renal Cell Carcinoma and Hepatocellular Carcinoma

SOUTH SAN FRANCISCO, Calif., May 16, 2012 (BUSINESS WIRE) -- -- Investor Briefing Webcast Will Review, Provide Context for Data

Exelixis, Inc. EXEL -1.38% reiterated its slate of activities in conjunction with the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5, 2012, in Chicago, Illinois. Clinical data for cabozantinib will be featured in four oral presentations, four poster discussion presentations, and one general poster presentation. The company will also host an investor briefing that will be webcast live on Monday, June 4, 2012.

The full roster of cabozantinib data presentations expected at the meeting appears below (all times Central Daylight). As data are presented at the meeting, the accompanying presentations and/or posters will be made available online via the Events page under Resources on www.exelixis.com .

Oral Presentations

-- "Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)" (Abstract #4504) Dr. Toni K. Choueiri, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA Oral Abstract Session: Genitourinary Cancer (Nonprostate) Saturday, June 2; 4:15 p.m.

-- "Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)" (Abstract #4007) Dr. Chris Verslype, Hepatology, University Hospitals Gasthuisberg, Belgium Oral Abstract Session: Gastrointestinal (Noncolorectal) Cancer Saturday, June 2; 5:15 p.m.

-- "An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline" (Abstract #5508) Dr. Patrick Schoffski, Department of General Medical Oncology, Catholic University Leuven, Belgium Clinical Science Symposium: Targeting Therapeutics for Thyroid Cancers Monday, June 4; 11:30 a.m.

-- "Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)" (Abstract #4513) Dr. Matthew R. Smith, Massachusetts General Hospital Cancer Center, Boston, MA Oral Abstract Session: Genitourinary Cancer (Prostate) Tuesday, June 5; 11:00 a.m.

Poster Discussion Presentations

-- "Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)" (Abstract #535; Poster Board #25) Dr. Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA Poster Discussion Session: Breast Cancer-HER2/ER Saturday, June 2; 1:15 p.m. - 5:15 p.m. (discussion to follow)

-- "Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)" (Abstract #8531; Poster Board #20) Dr. Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ Poster Discussion Session: Melanoma/Skin Cancers Saturday, June 2; 1:15 p.m. - 5:15 p.m. (discussion to follow)

-- "Investigator sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases" (Abstract #4566; Poster Board #20) Dr. Richard J. Lee, Massachusetts General Hospital Cancer Center, Boston, MA Poster Discussion Session: Genitourinary (Prostate) Cancer Monday, June 4; 8:00 a.m. - 12:00 p.m. (discussion to follow)

-- "Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT)" (Abstract #7514; Poster Board #4) Dr. Beth A. Hellerstedt, US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Texas Oncology, Central Austin Cancer Center, Austin, TX Poster Discussion Session: Lung Cancer - Non-small Cell Metastatic Tuesday, June 5; 8:00 a.m. - 12:00 p.m. (discussion to follow)

Poster Presentation

-- "Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC)" (Abstract #5547; Poster Board #22G) Dr. Maria E. Cabanillas, University of Texas MD Anderson Cancer Center, Houston, TX General Poster Session: Head and Neck Cancer Saturday, June 2; 1:15 p.m. - 5:15 p.m.

Details on May 16th Release of 2012 ASCO Annual Meeting Abstracts

The 2012 ASCO Annual Meeting abstracts featuring cabozantinib will be posted publicly on www.asco.org today, Wednesday, May 16, 2012, at 6:00 p.m. EDT. These abstracts were submitted to ASCO in early 2012 and do not incorporate data and new findings generated since that time. The latest and most up-to-date clinical data will be delivered during the investigators' presentations at the meeting itself, at the dates and times listed above.

Investor Briefing at the 2012 ASCO Annual Meeting

Exelixis will hold an investor briefing that will be webcast live on Monday, June 4, 2012, from 6:30-8:30 p.m. CDT. During the briefing, Exelixis management and other presenters will review and provide context for the latest clinical data for cabozantinib in medullary thyroid cancer, castration-resistant prostate cancer, and other tumor types, as presented at the ASCO Annual Meeting. In addition to Exelixis management, participants in the briefing will include:

-- Dr. Jose Baselga, Massachusetts General Hospital Cancer Center, Boston, MA

-- Dr. Toni Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA

-- Dr. Karim Fizazi, Institut Gustave Roussy, Paris, France

-- Dr. Daniel George, Duke University Medical Center, Durham, NC

-- Dr. Patrick Schoffski, Catholic University Leuven, Belgium

-- Dr. Steven Sherman, MD Anderson Cancer Center, Houston, TX

-- Dr. Matthew Smith, Massachusetts General Hospital Cancer Center, Boston, MA

The webcast will be accessible via the Event Calendar page under Investors at www.exelixis.com .

An archived replay of the webcast will be available on the Event Calendar page under Investors at www.exelixis.com and audio-only via phone until 11:59 p.m. EDT/8:59 p.m. PDT on July 11, 2012. Access numbers for the audio-only phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 35434695.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at http://www.exelixis.com .

SOURCE: Exelixis, Inc.

http://www.marketwatch.com/story/reminder-exelixis-announces-data-presentations-webcast-of-investor-briefing-in-conjunction-with-2012-asco-annual-meeting-2012-05-16

Mi blog

#1835

Re: Farmas USA

y cees que s bueno vender cuando parece que lo hará todo el mundo?o esperar a ver si tras la bajada de apertura pudiera rebotar algo?

#1836

Re: Farmas USA

ups!! pues si no me he equivocado, que no controlo el alemán y es la primera vez que veo lapágina, ahora mismo está a 4,13 euros... 5,42 usd

edito que me he quedado a medias: no esperáis más caída? está claro que es muucho, solo con el gap de apertura más la cotización se puede ir a un -20%, o es que yo me había planteado todo mucho más negativo?

#1840

Re: Farmas USA

una pregunta, el afterhour va a aparte del premarket?me explico;

las operaciones del after se ejecutan por un lado, y luego las del premarket van por otro ya para abrir la cotización? o el premarket empieza por donde termina el after?
vaya lío, creo que se entiende la pregunta